This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n4http://linked.opendata.cz/resource/domain/vavai/projekt/
n20http://linked.opendata.cz/resource/domain/vavai/subjekt/
n18http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n5http://bibframe.org/vocab/
n7http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F12%3A00056022%21RIV13-MZ0-00023001/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F12%3A00056022%21RIV13-MZ0-00023001
rdf:type
n18:Vysledek skos:Concept
rdfs:seeAlso
http://www.sciencedirect.com/science/article/pii/S0010865012000148
dcterms:description
Background: Cytomegalovirus (CMV) is a major cause of infection in the early period after heart transplantation (HTx). There are limited data comparing universal prophylaxis with preemptive treatment of CMV infection in HTx recipients. Therefore, the goal of this study was to evaluate efficacy and safety of both strategies. Methods: A total of 17 HTx recipients were prospectively enrolled in the universal prophylaxis group. This study cohort was matched with 18 HTx recipients who had the same immunosuppressive regimen and received preemptive therapy for CMV infection. All patients were CMV-seropositive. The study group received oral valganciclovir in a dose of 900 mg daily for 100 days. The second group was treated in case of CMV viraemia higher than 500 copies/ml. The incidence of CMV infection, other opportunistic infections and acute graft rejection and adverse events were evaluated at 3th, 6th and 12th months post-transplant. Results: Universal prophylaxis was tolerated in 87.5% of the patients for a period of 100 days. Leukopenia was the most frequent side-effect that appeared in 25% of this group. This strategy decreased the rate of asymptomatic CMV infection during the first 3 months after HTx (11.7% vs. 55.6%, p=0.006) compared with preemptive therapy. This positive effect was associated with lower incidence of acute graft rejection at 12 months of follow up (6.3% vs. 41.2%, p=0.015). Conclusion: Universal prophylaxis, with valganciclovir in CMV-seropositive HTx recipients, was acceptably safe and compared with preemptive therapy of CMV infection reduced the incidence of asymptomatic CMV infection and of acute graft rejection. Background: Cytomegalovirus (CMV) is a major cause of infection in the early period after heart transplantation (HTx). There are limited data comparing universal prophylaxis with preemptive treatment of CMV infection in HTx recipients. Therefore, the goal of this study was to evaluate efficacy and safety of both strategies. Methods: A total of 17 HTx recipients were prospectively enrolled in the universal prophylaxis group. This study cohort was matched with 18 HTx recipients who had the same immunosuppressive regimen and received preemptive therapy for CMV infection. All patients were CMV-seropositive. The study group received oral valganciclovir in a dose of 900 mg daily for 100 days. The second group was treated in case of CMV viraemia higher than 500 copies/ml. The incidence of CMV infection, other opportunistic infections and acute graft rejection and adverse events were evaluated at 3th, 6th and 12th months post-transplant. Results: Universal prophylaxis was tolerated in 87.5% of the patients for a period of 100 days. Leukopenia was the most frequent side-effect that appeared in 25% of this group. This strategy decreased the rate of asymptomatic CMV infection during the first 3 months after HTx (11.7% vs. 55.6%, p=0.006) compared with preemptive therapy. This positive effect was associated with lower incidence of acute graft rejection at 12 months of follow up (6.3% vs. 41.2%, p=0.015). Conclusion: Universal prophylaxis, with valganciclovir in CMV-seropositive HTx recipients, was acceptably safe and compared with preemptive therapy of CMV infection reduced the incidence of asymptomatic CMV infection and of acute graft rejection.
dcterms:title
Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients
skos:prefLabel
Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients
skos:notation
RIV/00023001:_____/12:00056022!RIV13-MZ0-00023001
n18:predkladatel
n20:ico%3A00023001
n3:aktivita
n14:P
n3:aktivity
P(NS9697), P(NT11262)
n3:cisloPeriodika
1-2
n3:dodaniDat
n6:2013
n3:domaciTvurceVysledku
n13:5693187 n13:4924789 n13:6980856 n13:6807437 n13:4136411 n13:9540628
n3:druhVysledku
n11:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n7:predkladatel
n3:idSjednocenehoVysledku
128098
n3:idVysledku
RIV/00023001:_____/12:00056022
n3:jazykVysledku
n9:eng
n3:klicovaSlova
Rejection; Prophylaxis; Infection; Heart transplantation; Valganciclovir; Cytomegalovirus
n3:klicoveSlovo
n12:Cytomegalovirus n12:Infection n12:Rejection n12:Valganciclovir n12:Prophylaxis n12:Heart%20transplantation
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[14BEC5009D67]
n3:nazevZdroje
Cor et Vasa
n3:obor
n19:FA
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
6
n3:projekt
n4:NT11262 n4:NS9697
n3:rokUplatneniVysledku
n6:2012
n3:svazekPeriodika
54
n3:tvurceVysledku
Málek, Ivan Gazdič, Tomáš Vymětalová, Jevgenija Kubánek, Miloš Vrbská, Jana Kautzner, Josef
s:issn
0010-8650
s:numberOfPages
7
n5:doi
10.1016/j.crvasa.2012.01.009